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ABSTRACT: Cocrystals offer great promise in enhancing drug aqueous solubilities, but face
the challenge of conversion to a less soluble drug when in contact with solvent. This manuscript
shows that differential solubilization of cocrystal components by micelles can impart thermo-
dynamic stability to otherwise unstable cocrystals. The theoretical foundation for controlling
cocrystal solubility and stability is presented by considering the contributions of micellar solubi-
lization and ionization of cocrystal components. A surfactant critical stabilization concentration
(CSC) and a solution pH (pHmax) where cocrystal and drug are thermodynamically stable are
shown to characterize cocrystal stability in micellar solutions. The solubility, CSC, and pHmax of
carbamazepine cocrystals in micellar solutions of sodium lauryl sulfate predicted by the models
are in very good agreement with experimental measurements. The findings from this work
demonstrate that cocrystal CSC and pHmax can be tailored from the selection of coformer and
solubilizing additives such as surfactants, thus providing an unprecedented level of control over
cocrystal stability and solubility via solution phase chemistry. © 2011 Wiley-Liss, Inc. and the
American Pharmacists Association J Pharm Sci 100:5219–5234, 2011
Keywords: acid–base equilibria; cocrystals; crystal engineering; solubility; stabilization;
surfactants; thermodynamics; pH; micelle
INTRODUCTION
The ability to engineer the aqueous solubility of inher-
ently insoluble pharmaceutical compounds by cocrys-
tal formation has important implications for the de-
velopment of drug delivery systems. Cocrystals owe
their large solubility range to the numerous struc-
tures, diverse molecular characteristics of cocrystal
components, and solution phase behavior.1,2 One of
the fundamental consequences related to the nature
of cocrystal components and their solution phase be-
havior is the ability to tailor the solubility–pH depen-
dence of cocrystals of nonionizable or ionizable drugs
by careful selection of coformers and control of so-
lution conditions. The contributions of ionization and
complexation of cocrystal components to cocrystal sol-
ubility have been reported and quantitative models
have been developed that allow for tailoring cocrys-
tal solubility behavior.3–5 Although surfactants are
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commonly used in cocrystal dissolution studies and
formulations,6–8 and the role of micelles in drug solu-
bilization is widely appreciated in the literature,9–14
their role in cocrystal solubility has been virtually
unexplored.
Cocrystals that are more soluble than the parent
drug can transform, sometimes very rapidly, to a less
soluble drug upon contact with solution.15–18 Thus,
understanding and controlling cocrystal thermody-
namic stability is essential if they are to become phar-
maceutical products.
We recently showed that surfactants can impart
thermodynamic stability to cocrystals that are oth-
erwise unstable in solution.19,20 A surfactant criti-
cal stabilization concentration (CSC) was discovered
where cocrystal and drug phases became thermody-
namically stable in micellar solutions. Below CSC,
cocrystals are thermodynamically unstable, whereas
at CSC and above, cocrystals are thermodynamically
stable. A theoretical treatment predicted that the
stabilizing effect of micellar surfactants is related
to their differential solubilization of cocrystal com-
ponents. In other words, when a surfactant system
has superior solubilization power for the least soluble
cocrystal component, its effectiveness as a cocrystal
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stabilizer increases. These findings extend to multi-
ple additives and solubilization mechanisms, includ-
ing complexing agents and polymers.
The work presented here establishes the contri-
butions of micellar solubilization and ionization of
cocrystal components on cocrystal solubility, develops
mathematical models that predict cocrystal solubility
behavior in terms of thermodynamic parameters that
are readily available in the literature or experimen-
tally accessible, and provides a mechanistic basis for
tailoring cocrystal CSC and pHmax to meet solubility
and stability requirements.
This work shows for the first time that micellar
solubilization can induce a pHmax for cocrystals that
do not have one otherwise. Mathematical models are
derived that describe the dependence of cocrystal sol-
ubility, CSC, and pHmax on cocrystal solubility prod-
uct (Ksp), components Ks(s) and Ka(s), and micellar
surfactant concentration.
The predictive power of the models is evalu-
ated from studies that examine the influence of
a surfactant (sodium lauryl sulfate, SLS) and co-
former ionization on cocrystal solubility, stability,
and CSC for a range of cocrystals of a hydropho-
bic, nonionizable drug (carbamazepine, CBZ) and
hydrophilic coformers with several ionization prop-
erties and stoichiometries. The cocrystals stud-
ied include the following: 1:1 carbamazepine–sali-
cylic acid (CBZ–SLC), 1:1 carbamazepine–saccharin
(CBZ–SAC), 2:1 carbamazepine–succinic acid (CBZ—
SUC), and 2:1 carbamazepine–4-aminobenzoic acid
monohydrate (CBZ–4ABA-HYD). The selected cocrys-
tals cover the two most abundant stoichiometries,
and the coformers have ionization properties common
among reported cocrystals. SLC and SAC are mono-
protic weak acids; SLC has a reported pKa of 3.0,21
SAC has a range of reported pKa values between 1.8
and 2.2.22,23 SUC is a diprotic weak acid with pKa
values of of 4.1 and 5.6.24 4ABA is amphoteric with
pKa values of 2.6 and 4.8.25
THEORETICAL
This section describes the theoretical basis of our
quantitative approach to predict cocrystal solubiliza-
tion and thermodynamic stability from solution phase
properties of cocrystal components and micellar sur-
factants. We first present the solution phase equilib-
ria that govern the solubilization properties of cocrys-
tals in micellar solutions. Relatively simple equations
to calculate cocrystal solubility are derived by con-
sidering the contributions of ionization and micellar
solubilization of cocrystal components. Several im-
portant physicochemical factors are identified that
can be used to make cocrystal solubility and stability
predictions.
The interested reader is directed to the supporting
information for derivations of the equations presented
in this section. The analysis can be generalized to
mixed micelles and other solubilization mechanisms,
although they may be of a different nature.
Cocrystal Solubilization and Thermodynamic
Stabilization in Micellar Solutions
A micellar solution phase in equilibrium with a
solid cocrystal phase consists of molecules of cocrys-
tal components and surfactant in several states of
self-association, complexation, and ionization. Surfac-
tants self-assemble in solution at a critical micellar
concentration (CMC) and provide a means to solubi-
lize cocrystal components. The solubility of a cocrystal
(RHA) composed of the nonionized forms of its com-
ponents, a nonionizable drug (R) and an ionizable co-
former, in this case, a monoprotic weak acid (HA), is
described by the equilibria for cocrystal dissociation,
ionization, complexation, and micellar solubilization.
For the sake of simplicity, solution complexation of
cocrystal components is assumed to be negligible and
the expressions for other equilibria are
RHAsolid
Ksp←→ Raq + HAaq (1)
HAaq
Ka←→ A−aq + H+aq (2)
Raq + M K
R
s←→ Rm (3)







where subscripts m and aq refer to micellar and aque-
ous pseudophases, respectively. Ksp is the cocrystal
solubility product and Ka is the dissociation constant
for acidic coformer. M is the micellar surfactant. KsR,
KsHA, and KsA– are the micellar solubilization con-
stants for cocrystal components and their ionized
forms.
The cocrystal solubility, SRHA,T, under stoichiomet-
ric conditions, is equal to the total concentration of
each cocrystal component in equilibrium with the so-
lution, SRHA,T = [R]T = [A]T. The contributions of ion-
ization and micellar solubilization of each cocrystal











= [HA]aq + [A−]aq + [HA]m + [A−]m (6)
An expression for cocrystal solubility in terms
of experimentally accessible solution properties is
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obtained:
SRHA,T =


































































where the terms in brackets refer to concentrations,
with the recognition that under dilute solution condi-
tions they approximate activities.
Equation 7 can be further simplified to
SRHA,T =




] + KHAs [M]
)
(13)
when KsHA  KsA–, and the micellar solubilization of
ionized species negligibly affects total solubility un-
less present at very high concentrations.26–28 Equa-
tion 13 predicts that cocrystal solubility increases
with increasing cocrystal Ksp, components KsR and
KsHA, coformer ionization Ka/[H+], and surfactant mi-
cellar concentration, [M].
It is evident from Equations 7 and 13 that cocrys-
tal solubility is not linearly dependent on micellar
concentration. This is in contrast to the well-known
linear dependence of the micellar solubilization of









where SR,aq is the solubility of crystal R in the aqueous
pseudophase. In this analysis, Ks values are assumed
to be independent of solute and surfactant concentra-
tions.
Equations 13 and 14 are shown graphically in Fig-
ure 1 for the case of a nonionizable, hydrophobic drug
and its cocrystal with an ionizable, hydrophilic co-
former where KsHA = 0. This plot reveals that cocrys-
tal and drug solubility surfaces intersect along a curve
Figure 1. Cocrystal RHA (blue/green surface) and drug
R (yellow surface) solubility dependence on surfactant con-
centration and pH. The intersection of the cocrystal and
drug solubility surfaces represents the surfactant concen-
trations (CSC) and pH values (pHmax), where cocrystal and
drug are in thermodynamic equilibrium with the solution.
Solubilities were calculated from Equations 13 and 14, with
Ksp = 1 mM2 (SRHA,aq/SR,aq = 5), SR,aq = 0.2 mM, pKa = 4,
KsR = 1 mM–1, KsHA = 0, and CMC = 8 mM.
of given surfactant concentration and pH values and
identifies stability regions for cocrystal or drug by two
critical parameters. The first is the CSC or the sur-
factant concentration where cocrystal and drug solid
phases are in equilibrium with the solution. The sec-
ond is the pHmax or the pH value at the CSC. Below
the CSC or above pHmax, the cocrystal is thermody-
namically unstable and conversion to solid drug is
favorable. Above the CSC or below pHmax, the cocrys-
tal becomes the thermodynamically stable phase, and
conversion to solid drug is not possible. Cocrystal for-
mation in this region is, however, favorable in the
presence of a coformer. When one or more cocrystal
components ionize, both CSC and pHmax are neces-
sary to describe the solution conditions under which
cocrystal and/or drug solid phase are thermodynami-
cally stable.
The existence of CSC and pHmax (in the case of ion-
izable cocrystal component) is a consequence of the
lower rate of increase of cocrystal solubility with sur-
factant concentration as compared with that of drug
solubility. It is evident from Equations 13 and 14 that
cocrystal solubility depends on
√
[M] (when KsHA =
0), whereas the drug solubility depends on [M].
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 100, NO. 12, DECEMBER 2011
5222 HUANG AND RODRÍGUEZ-HORNEDO
Estimation of Cocrystal Solubilization from Drug
Solubilization
A useful estimate of the surfactant influence on
cocrystal solubilization can be calculated from the








This expression is obtained by combining Equa-
tions 13 and 14 for a nonionizable drug R when KsR
is unaffected by the coformer and KsHA = 0. A surfac-
tant concentration that increases drug solubility by
100-fold is predicted to increase cocrystal solubility
by 10-fold. Equation 15 implies that a surfactant will
increase the solubility of all 1:1 cocrystals of a drug
by the same ratio as long as the stated assumptions
are justified.











for a nonionizable drug R and coformer X. The solubil-
ity increase for a 2:1 cocrystal is predicted to be 1002/3
or 21.5-fold its aqueous solubility when the drug sol-
ubility is increased by 100-fold. Thus cocrystal stoi-
chiometries richer in hydrophobic drug will exhibit a
weaker dependence of total cocrystal solubility on mi-
cellar solubilization, leading to higher CSC or pHmax
values.
Mechanism by Which Micelles Stabilize Cocrystals
The influence of micellar solubilization on cocrystal
thermodynamic stability and CSC can be explained
by considering the species distribution in micellar so-
lutions at equilibrium with cocrystal and/or drug solid
phases. Figure 2 shows the distribution of the drug in
micellar and aqueous environments for a crystal of
a hydrophobic drug R and its cocrystal with a hy-
drophilic coformer HA under nonionizing conditions
where KsHA = 0.
When drug crystal phase (R) is in equilibrium with
the micellar solution, the drug concentration in the
aqueous environment, [R]R,aq, remains constant with
increasing surfactant concentration. At surfactant
concentrations above CMC, the drug concentration in
the micellar environment, [R]R,m, increases linearly.
For cocrystal (RHA) in equilibrium with the micellar
solution (where drug is solubilized by the micelle and
the coformer is not), the drug concentration in the
aqueous environment, [R]RHA,aq, is not constant, but
decreases with increasing surfactant concentration
above CMC. Because the coformer is not solubilized by
the micelle, the aqueous phase becomes enriched with
Figure 2. Distribution of drug (R) between the aque-
ous and micellar environments in surfactant solutions at
equilibrium with the cocrystal (RHA) and crystal (R). The
cocrystal thermodynamic stability relative to the drug de-
creases with surfactant concentration. A thermodynami-
cally unstable cocrystal in pure solvent becomes stable at
the CSC where all curves intersect. Cocrystal is more sol-
uble than the drug below CSC, equally soluble to drug at
CSC, and less soluble than the drug above CSC. Subscripts
aq, m, and T, refer to aqueous, micellar, and total. Solubili-
ties and drug distributions were calculated from Equations
13 and 14, with Ksp = 1 mM2, KsR = 0.5 mM–1, KsHA = 0 ,
SR,aq = 0.5 mM, and CMC = 8 mM.
coformer and [R]RHA,aq decreases to maintain a con-
stant solubility product as described by the cocrystal
dissociation equilibrium. This imbalance of cocrystal
components in the aqueous environment dampens the
increase in the total cocrystal solubility, as drug sol-
ubilized by the micelle increases with surfactant con-
centration. A CSC where cocrystal is in equilibrium
with the drug is reached as indicated by the intersec-
tion of the total drug concentration curves, [R]RHA,T =
[R]R,T, as well as the speciation in the aqueous and mi-
cellar environments, [R]RHA,aq = [R]R,aq and [R]RHA,m
= [R]R,m.
CSC and pHmax Dependence on Cocrystal
and Surfactant Properties
Cocrystals with higher solubilities in water are pre-
dicted to exhibit higher CSC values as illustrated in
Figure 3. For cocrystals of the same drug, aqueous
solubilities can be altered by different coformers or by
coformer ionization behavior in solution (by adjusting
solution pH).
The influence of cocrystal aqueous solubility on
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Figure 3. Influence of surfactant solubilization on cocrys-
tal solubility and CSC for cocrystals of the same drug with
different aqueous solubilities. More soluble cocrystals rel-
ative to the drug require higher surfactant concentrations
to achieve CSC. Total solubilities of cocrystal RHA (SRHA,T)
and drug (SR,T) were calculated from Equations 13 and 14,
with cocrystal Ksp = 1 and 4 mM2 (SRHA,aq/SR,aq = 5 and 10),
SR,aq = 0.2 mM, KsR = 1 mM–1, KsHA = 0, and CMC = 8 mM.
by solving for the surfactant concentration at which
SRHA,T = SR,T, from Equations 13 and 14. This ex-
pression applies to a 1:1 cocrystal with no micellar
solubilization of coformer and negligible solution com-
plexation of cocrystal components.
The influence of the drug and coformer micellar sol-
ubilization on CSC had been recently presented.19,20
The basis for the existence of the CSC for cocrystal
and drug was described from the differential micel-
lar solubilization of the drug and the coformer. The
greater the drug micellar solubilization, KsR, relative
to that of the coformer, KsHA, the lower is the CSC
value. In the case of pharmaceutical cocrystals, drugs
are generally much more hydrophobic than coformers
and KsR  KsHA.
Figure 4 shows the dependence of CSC on drug
micellar solubilization (KsR) and cocrystal aqueous
solubility, as predicted by Equation 17. CSC is in-
versely proportional to drug micellar solubilization
and directly proportional to cocrystal aqueous solu-
bility. This equation allows for estimation of the re-
quired KsR to achieve the CSC for the cocrystal and its
drug component, and in this way, provide guidance for
the rational selection of surfactant and concentration.
The choice of the right surfactant or combination of
surfactants and additives will depend on the desired
solubility advantage of cocrystal over drug and the
time over which it is to be sustained. In some cases,
Figure 4. The CSC increases with increasing cocrystal
to drug solubility ratio in pure water (or below CMC) and
with decreasing drug micellar solubilization, KsR. CSC cal-
culated from Equation 17, with KsHA = 0 and CMC = 8 mM.
lowering the solubility advantage by a small fraction
may protect cocrystals from conversion, whereas in
others, a longer stability may be desired and condi-
tions closer to the CSC required. Cocrystals can im-
part a response to environmental conditions that the
drug lacks, for example, pH sensitivity, and in this
way, provide opportunities for enhanced drug deliv-
ery besides solubility alone.
Micellar solubilization of cocrystal components can
also impart pHmax to a cocrystal that otherwise does
not have one, as shown in Figure 5. The solubili-
ty–pH dependence for a cocrystal RHA of a nonion-
izable drug and a weakly acidic coformer, where the
cocrystal is more soluble than drug R at all pH values,
is presented in Figure 5a. Many CBZ cocrystals, in-
cluding CBZ–SAC, CBZ–SLC, and CBZ–4ABA-HYD,
have been shown to exhibit this behavior and, conse-
quently, have no pHmax in water.4,29,30 This behavior,
however, is changed by micellar solubilization and
ionization of cocrystal components (Fig. 5b), where
the cocrystal and drug solubility curves intersect at
a given pH, or pHmax. The surfactant concentration
at this intersection is the CSC. The drug micellar
solubilization leading to coformer enrichment in the
aqueous environment is responsible for the CSC and
pHmax.
Considering the contributions of coformer solubi-
lization and ionization in addition to drug solubiliza-
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Figure 5. pHmax of a cocrystal can be tailored by micellar solubilization of cocrystal com-
ponents. Solubility–pH dependence for a cocrystal RHA and drug R (a) in water and (b) in a
micellar solution. Calculations are based on Equation 18, with Ksp = 1 mM2 (SRHA,aq/SR,aq = 5),
SR,aq = 0.2 mM, [M] = 99 mM (SR,T/SR,aq = 100 and SRHA,T/SRHA,aq = 10), pKa = 4, KsR = 1 mM–1,
and KsHA = 0.
where [H+] represents [H+]max. According to Equa-
tion 18, the CSC for a 1:1 cocrystal RHA is dependent
on several critical parameters: Ksp/S2R,aq, Ka, [H+],
KsR, and KsHA. This equation can also be solved for
[H+] to predict the pHmax dependence on micellar sur-
factant concentration and other cocrystal and surfac-
tant properties. Equation 18 and Figure 6 show that
if a CSC exists, there is also a pHmax value associated
with that CSC and vice versa. CSC is predicted to
increase as ionization increases. Higher levels of ion-
ization increase cocrystal solubility and, thus, more
surfactant is required to achieve the CSC. Equation
18 can also be used to engineer a cocrystal pHmax
based on selection of an appropriate surfactant and
concentration.
Table 1 summarizes the equations that describe
cocrystal solubility and CSC for several common
classes of cocrystals with varying stoichiometries and
component ionization properties.
The theoretical treatment of cocrystal micellar sol-
ubilization suggests that the CSC where cocrystal
and drug phases are in thermodynamic equilibrium
is most readily achieved by (1) preferential drug solu-
bilization (KsR  KsHA), (2) cocrystals of lower aque-
ous solubility relative to drug, and (3) cocrystal stoi-
chiometries that are higher in coformer.
MATERIALS AND METHODS
Materials
Anhydrous monoclinic CBZ(III) (lot #057K11612 US-
Pharmacopeia grade) was purchased from Sigma
Chemical Company (St. Louis, Missouri), stored at
5◦C over anhydrous calcium sulfate, and used as re-
ceived. SLC (lot #09004LH), SAC (lot #03111DD),
Figure 6. Critical stabilization concentration dependence
on pHmax according to Equation 18 for a cocrystal RHA.
CSC increases greatly at pH above the coformer pKa (i.e.,
increased ionization). Calculations are based on Equation
18, with Ksp = 1 mM2, SR,aq = 0.2 mM, KsR = 1 mM–1, KsHA
= 0, pKa = 4, and CMC = 8 mM.
SUC (lot #037K0021), 4ABA (lot #068K0698), and
SLS (lot #104H0667) were also purchased from Sigma
Chemical Company and used as received. Water used
in this study was filtered through a double deionized
purification system (Milli Q Plus Water System from
Millipore Company, Bedford, Massachusetts).
Cocrystal Synthesis
Cocrystals were prepared by reaction crystallization
method at room temperature by adding CBZ to nearly
saturated solutions of coformer.16 CBZ–SLC was
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 100, NO. 12, DECEMBER 2011 DOI 10.1002/jps
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prepared in acetonitrile, CBZ–SAC and CBZ–SUC
were prepared in ethanol, and CBZ–4ABA-HYD was
prepared in water. CBZ dihydrate (CBZD) was pre-
pared in water. Solid phases were characterized by
X-ray powder diffraction (XRPD).
CSC Measurement from Solid Phase Stability (Method 1)
Cocrystals were suspended in aqueous solutions
of different SLS concentrations. Suspensions were
seeded with approximately 5% (w/w) of CBZD after
several hours. CBZ–SLC or CBZ–SAC (30–40 mg) was
added to 3 mL of aqueous SLS solution. CBZ–SUC or
CBZ–4ABA-HYD (70–80 mg) was added to 3 mL of
aqueous SLS solution. Samples were maintained at
25 ± 0.1◦C for a duration of 3 days, when the solids
were recovered and analyzed by XRPD. Examination
of the XRPD patterns revealed that 24 h was suffi-
cient for the samples to reach equilibrium. The CSC
was determined to be above the highest SLS concen-
tration where CBZD is detected and below the lowest
concentration where CBZD is no longer detected in
the solid phase.
CSC Predicted from Cocrystal Aqueous Solubility and
Micellar Solubilization of Cocrystal Components
(Method 2)
Critical stabilization concentration was predicted
from equations given in Table 1 (Eqs. 18, 24, and
26), with thermodynamic parameters measured in
pure water or obtained from the literature. Ksp was
calculated from cocrystal aqueous solubilities accord-
ing to the equations given in Table 1 (Eqs. 13, 23,
and 25 when [M] = 0); cocrystal aqueous solubili-
ties were determined by measuring eutectic concen-
trations of the drug and the coformer in pure wa-
ter at 25 ± 0.1◦C. Cocrystals (50–100 mg) and CBZD
(25–50 mg) were suspended in 3 mL of pure water up
to 3 days. pH at equilibrium was measured, but not
independently modified. Cocrystal aqueous solubility
was calculated from eutectic concentration measure-













4 for 1:1 and 2:1 cocrystals, re-
spectively. These equations consider ionization and
micellar solubilization of cocrystal components. The
evaluation of cocrystal solubilities and stabilities
via eutectic points has been discussed thoroughly
elsewhere.4,29,31 At the eutectic or transition point,
the solution is saturated with respect to two solid
phases, in this case, cocrystal and CBZD. This method
allows for cocrystal solubility measurement under
thermodynamic equilibrium that may not otherwise
be accessible due to transformation to less soluble
forms.
Micellar solubilization constants (Ks) for cocrystal
components were determined by linear regression of
the measured solubilities of the individual compo-
nents as a function of micellar SLS concentration
at 25 ± 0.1◦C. Ka values were obtained from liter-
ature. Drug and coformer concentrations were an-
alyzed by high-performance liquid chromatography
(HPLC). Solid phases at equilibrium were confirmed
by XRPD.
CSC Measurement of Cocrystal Solubility in SLS
Solutions (Method 3)
Critical stabilization concentration was evaluated by
measuring cocrystal and drug solubilities as a func-
tion of SLS concentration in water at 25 ± 0.1◦C.
Cocrystal solubilities were obtained by measuring eu-
tectic concentrations of drug and coformer in aqueous
SLS solutions at 25 ± 0.1◦C. Cocrystal (50–100 mg)
and CBZD (25–50 mg) were suspended in 3 mL of
pure water up to 3 days. pH at equilibrium was
measured, but not independently modified. Cocrys-














for 1:1 and 2:1 cocrystals, respectively. The equa-
tions consider ionization and micellar solubilization
of cocrystal components. CBZD solubilities were mea-
sured as a function of SLS concentration in water
at 25 ± 0.1◦C and are consistent with the reported
values.32 Drug and coformer concentrations were an-
alyzed by HPLC. Solid phases at equilibrium were
confirmed by XRPD.
High-Performance Liquid Chromatography
The solution concentrations of CBZ and coformer were
analyzed by Waters HPLC (Milford, Massachusetts)
equipped with an ultraviolet–visible spectrometer
detector. Waters’ operation software, Empower 2
(Waters), was used to collect and process the data. A
C18 Thermo Electron Corporation (Quebec, Canada)
column (5:m, 250 × 4.6 mm) at ambient tempera-
ture was used. The mobile phase composed of 55%
methanol and 45% water with 0.1% trifluoroacetic
acid, and the flow rate was 1 mL/min using an iso-
cratic method. Injection sample volume was 20 or
40:L. Absorbance of CBZ, SAC, SLC, SUC, and 4ABA
was monitored at 284, 260, 303, 230, and 284 nm, re-
spectively.
X-ray Powder Diffraction
X-ray powder diffraction diffractograms of solid
phases were collected with a benchtop Rigaku Mini-
flex X-ray diffractometer (Rigaku, Danvers, Mas-
sachusetts) using Cu K" radiation (8 = 1.54 Å), a tube
voltage of 30 kV, and a tube current of 15 mA. Data
were collected from 5◦ to 40◦ at a continuous scan
rate of 2.5◦/min.
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Figure 7. X-ray powder diffraction (XRPD) patterns showing the influence of SLS concentra-
tion on the cocrystal to drug conversion at 25◦C for (a) CBZ–SLC at pH 3.0, (b) CBZ–SAC at
pH 2.2, (c) CBZ–4ABA-HYD at pH 4.0, and (d) CBZ–SUC at pH 3.1. pH was not independently
adjusted and represents the values measured at 24 h before solid phase recovery for XRPD
analysis. Initial solid phase consisted of the cocrystal and a small fraction of CBZD. Peaks
associated with SLS are indicated by ∗.
RESULTS
The equations presented in the theoretical section for
cocrystal solubility in terms of micellar solubilization
and ionization of cocrystal components suggest that
cocrystal CSC and pHmax in micellar solutions can
be a priori calculated from knowledge of cocrystal
and drug solubilities in water, Ka and Ks values of
cocrystal components, and surfactant CMC. At the
CSC, cocrystals otherwise unstable in aqueous me-
dia will become thermodynamically stable. To eval-
uate the predictive power of the model, the solubil-
ity and stability of cocrystals of a nonionizable drug
(CBZ) with coformers of different ionization proper-
ties and stoichiometries were investigated as a func-
tion of SLS solution concentration. These included 1:1
cocrystals where coformers are monoprotic weak acids
(CBZ–SLC and CBZ–SAC) and 2:1 cocrystals with
a diprotic weak acid (CBZ–SUC) or with an ampho-
teric coformer (CBZ–4ABA-HYD). The cocrystal aque-
ous solubilities range from 1.32 mM for CBZ–SLC to
2.38 mM for CBZ–SUC (expressed in terms of drug
concentration) at 25◦C, or 2.5–4.5 times the solubility
of CBZD (0.53 mM).32 Cocrystal solubilities in pure
water are in agreement with those reported in previ-
ous studies.29
For cocrystals with ionizable components, the CSC
is dependent on pH, and although the pH was not
independently adjusted in these studies, the pH of
surfactant solutions at equilibrium with solid phases
was measured. The pH at the CSC corresponds to
pHmax, where two solid phases (cocrystal and drug in
this case) are in equilibrium with the solution.
The cocrystal CSCs were evaluated by three meth-
ods: (1) measurement of solid phase stability and
pH as a function of SLS solution concentration, (2)
calculation from cocrystal and drug solubility mea-
surement in pure water, in conjunction with val-
ues of cocrystal component ionization (Ka), micel-
lar solubilization (Ks), surfactant CMC, and solu-
tion pH, and (3) measurement of cocrystal solubility,
drug solubility, and pH as a function of SLS solu-
tion concentration. Further, the dependence of CSC on
pHmax was estimated from the evaluation of CSC at a
single pH.
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Figure 8. Calculated solubility and CSC of CBZ cocrystals in SLS aqueous solutions, from
measured solubility in water and values of Ks, Ka, and pH listed in Table 2. Values of solu-
tion pH measured at equilibrium with solid phases are indicated. Dashed line shows the SLS
concentration at the CSC, where the cocrystal and drug are thermodynamically stable. Solid
lines represent solubility predictions for cocrystal and drug, according to Equations 13, 14, 23,
and 25. A CMC value of 6 mM for SLS measured at saturation with CBZD was used in these
calculations.
CSC from Measurement of Solid Phase
Stability (Method 1)
Evaluation of the CSC from cocrystal phase stabil-
ity measurements was carried out by XRPD analy-
sis of solid phases after suspension in aqueous solu-
tions of varying SLS concentration for 72 h, though
24 h was sufficient for equilibration to occur. Figure
7 shows that cocrystal conversion to drug (CBZD) de-
creases and becomes undetectable as surfactant con-
centration increases. An incremental variation of SLS
concentrations for each cocrystal studied led to the
following range of CSC values: CBZ–SLC 15 mM <
CSC ≤ 20 mM, CBZ–SAC 50 mM < CSC ≤ 55 mM,
CBZ–4ABA-HYD 69 mM < CSC ≤ 104 mM, and
CBZ–SUC 120 mM < CSC ≤ 140 mM. The solution
pH value associated with each CSC measurement is
reported in the legend of Figure 7. The CSC range for
CBZ–SLC is in agreement with the previous results
where the cocrystal was found to be stable in 35 mM
(1%, w/v) SLS.19
Although the solid phase analysis approach is con-
venient for a quick assessment of the CSC range, it
must be recognized that its accuracy is limited by the
changes of solution composition from initial to equilib-
rium states as solid phase(s) dissolve and crystallize.
It is also not sufficient to establish whether the sta-
bilization achieved is of a thermodynamic or kinetic
nature. These issues may be resolved by measuring
the changes in solution composition that result from
equilibration of the cocrystal and solid drug with the
solution phase and/or calculating the CSC according
to the equations presented here.
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Table 2. Cocrystal Ksp and Drug Solubilities in Water, pKa and Ks Values for Cocrystal Components in SLS Solutions Used in
Calculation of CSC and pHmax
Solid Phase Ksp (mM2 or mM3) pKa KsCBZ (mM–1) Kscoformer (mM–1) Aqueous Solubility (mM CBZ)
CBZ–SLC (1:1) 0.88 3.0a 0.58b 0.060 1.32 ± 0.06 (pH 3.0)
CBZ–SAC (1:1) 2.08 2.0c 0.58b 0.013 2.36 ± 0.05 (pH 2.2)
CBZ–4ABA–HYD (2:1) 2.56 2.6, 4.8d 0.49e <0.010f 1.83 ± 0.02 (pH 4.0)
CBZ–SUC (2:1) 6.15 4.1, 5.6g 0.49e <0.010f 2.38 ± 0.02 (pH 3.1)
CBZD NA N/A 0.49 (0–140 mM)
0.58 (0–50 mM)
n/a 0.53 ± 0.01h
aFrom Ref. 21.
bAverage Ks in lower concentrations of SLS (0–50 mM).
cFrom Refs. 22,23.
dFrom Ref. 25.
eAverage Ks in higher concentrations of SLS (0–140 mM).
fKs values < 0.010 mM–1 are considered equal to zero in calculations.
gFrom Ref. 24.
hFrom Ref. 32.
CSC from Measured Cocrystal Solubility in
Pure Water (Method 2)
Figure 8 shows the calculated cocrystal and drug sol-
ubilities in micellar SLS solutions according to Equa-
tions 13, 23, and 25 for the cocrystal and Equation
14 for the drug, from thermodynamic parameter val-
ues presented in Table 2. The CSC where the cocrys-
tal and CBZD are in equilibrium with the solution is
given by the SLS concentration and pH at the inter-
section of the solubility curves. The pH at the CSC cor-
responds to the pHmax. CSC is strongly influenced by
pH, and the calculations were carried out for pH val-
ues measured at saturation. This pH value changed
by 0.2 units or less at the concentrations of SLS
studied.
Predicted CSC values for these cocrystals range
from 20 to 187 mM, which are in reasonably good
agreement with the experimentally measured values
listed in Table 3. Results of CSC measurement ac-
cording to method 3 from solubility measurement in
surfactant solutions are described in the next section.
The range of measured CSCs for each cocrystal by
direct experimental measurement (methods 1 and 3)
can be narrowed by examining smaller increments of
SLS concentrations and by approaching equilibrium
from above and below saturation with respect to the
cocrystal and drug phases. Estimation of CSC from
thermodynamic properties of cocrystal and surfac-
tant solutions (such as solubility in water, Ks, Ka, and
CMC) provides useful guidance for the selection of
surfactant, its concentration and solution pH, and de-
creases the number of experiments required by other
methods.
Table 2 presents the thermodynamic parameter
values for the CBZ cocrystals studied. Cocrystal
Ksp in water and the corresponding solubility and
pH are within 30% of those reported in previous
studies.19,20,29 Coformer Ka values were obtained
from the literature. Surfactant CMC and Ks values
for the drug and coformer were determined from sol-
ubility measurements of individual components (drug
or coformer) in SLS solutions. The CMC of SLS was
experimentally measured to be 6 mM in solutions sat-
urated with CBZ and is used in these calculations un-
less otherwise specified. The reported CMC value for
SLS in water (8.3 mM, Ref.33) is higher than the value
measured in this study and those reported for CBZ
solutions without coformer (5.3 mM, Ref.32). The pu-
rity, ionic strength, and interactions with the solutes
are well documented to induce changes in the CMC
of ionic surfactants.9,34–36 Ks values for hydrophobic







Phase Stability in SLS
Solutions (Method 1)a
Predicted from Measured
Cocrystal Solubility in Water
(Method 2)b
Measured from Cocrystal
Solubility in SLS Solutions
(Method 3)c
CBZ—SLC (1:1) 3.0 2.5 15 < CSC ≤ 20 23 (CMC = 9 mM)
20 (CMC = 6 mM)
18 < CSC < 27
CBZ—SAC (1:1) 2.2 4.5 50 < CSC ≤ 55 44 35 < CSC < 50
CBZ–4ABA–HYD (2:1) 4.0 3.5 69 < CSC ≤ 104 92 70 < CSC < 140
CBZ—SUC (2:1) 3.1 4.5 120 < CSC ≤ 140 187 140 < CSC
aMethod 1: CSCs determined from XRPD analysis of the solid phase in Figure 7. The lower boundary is the highest concentration of SLS where
CBZD is detected in the solid phase, and the upper boundary is the lowest concentration of SLS where no CBZD is detected in the solid phase.
bMethod 2: CSCs calculated according to Equations 18, 24, and 26 given in Table 1, from Ksp, pKa, and Ks values in Table 2.
cMethod 3: CSCs determined from measurement of cocrystal and drug solubilities in SLS solutions (Figure 9–11).
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Figure 9. Influence of pH and surfactant concentration on cocrystal solubility for (a)
CBZ–SLC, (b) CBZ–SAC, (c) CBZ–4ABA-HYD, and (d) CBZ–SUC. Circles represent cocrystal
solubilities measured in surfactant solutions, whereas surfaces represent cocrystal solubilities
calculated from Equations 13, 23, and 25 using measured cocrystal solubility in water at a given
pH and thermodynamic values listed in Table 2.
compounds have been reported to be influenced by the
solute and surfactant concentrations.9,37–41 Ks values
as well as the concentration ranges in which they were
measured is shown in Table 2. An expression that de-
scribes the Ks dependence on surfactant concentra-
tion could also be used for more accurate predictions.
CSC from Measured Cocrystal Solubility in SLS Solutions
Figure 9 shows the experimental and predicted
cocrystal solubility dependence on surfactant con-
centration and pH. The pH was not independently
adjusted, and experimental measurements represent
the narrow pH range of micellar solutions saturated
with the cocrystal. Changes in pH, however, can pro-
foundly affect the cocrystal solubility as indicated by
the surfaces predicted from Equations 13, 14, 23, and
25 using parameter values given in Table 2. Coformer
ionization, in this case, determines the shape of the
curves because the drug is not ionizable and the co-
former is not solubilized by micelles. The solubility
of cocrystals with acidic coformers increases with the
pH, whereas solubility decreases and increases with
an amphoteric coformer. The contribution of coformer
ionization to cocrystal solubility is consistent with the
behavior in water, which we previously reported.4
Figures 10 and 11 show the predicted and mea-
sured cocrystal and drug solubilities as a function of
surfactant concentration. The CMC for SLS was con-
stant at 6 mM for cocrystals in Figure 9, whereas a
CMC of 9 mM was estimated from the solubility of
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Figure 10. Experimental and predicted influence of SLS
on drug (CBZD) solubility and CBZ cocrystal solubilities
for (a) CBZ–SAC, (b) CBZ–4ABA-HYD, and (c) CBZ–SUC.
Experimental solubilities were measured in unbuffered sur-
factant aqueous solutions. The pH measured at equilibrium
is indicated. Symbols (circles and triangles) represent the
experimental values. Predicted drug and cocrystal solubili-
ties (solid lines) were calculated according to Equations 13,
14, 23, and 25, with thermodynamic values listed in Table
2. The CSC is indicated by the SLS concentration (dashed
line) at the intersection of the predicted cocrystal and drug
solubility curves.
CBZ–SLC cocrystal (Fig. 10). Results show very good
agreement between the predicted and experimental
cocrystal solubility and CSC behavior. The largest
deviations were observed with the CBZ–SUC cocrys-
tal at high SLS concentration and may be a result
of changes in Ks with surfactant and coformer con-
centrations. The CSC values obtained by the three
methods are listed in Table 3 and show very good
agreement between the predicted (method 2) and ex-
perimentally measured CSC values (methods 1 and
3). A small variation in the CMC of SLS, such as from
6 mM to 9 mM for CBZ–SLC, has a relatively minor
impact on the CSC (20–23 mM).
Improving the predictive power of the model re-
quires more rigorous consideration of various solu-
tion interactions on equilibrium constants (such as
Ka and Ks) and on the surfactant properties (such as
CMC). The model equations assume that solubiliza-
tion of one cocrystal component is unaffected by the
presence of the other; that is, Ks for a component un-
der pure conditions is a good approximation for the Ks
in the presence of a cocrystal. Factors that cause Ks,
Ka, and CMC to change (such as ionic strength) in-
fluence the predictions, and these differences may be
considered by measuring the parameters as a func-
tion of solution composition. A 0.2-unit pH or pKa
change when pH ≈ pKa (e.g., CBZ–SAC) can lead to
errors in the CSC of the order of 15%–30%, and even
greater errors when pH > pKa. A 10% error in KsCBZ
(e.g., CBZ–SUC) leads to an error of 10% in the CSC.
An alternative approach would have been to fit the
models to the experimental data and evaluate the cor-
responding parameters. Given that this is the first
manuscript on this topic, we chose to use the thermo-
dynamic parameter values reported in the literature
or measured for single components of cocrystals to
evaluate the predicted cocrystal solubilities and CSC
values with all the established assumptions.
CSC and pHmax Dependence on Cocrystal and
Surfactant Properties
The treatment developed in the theoretical section is
based on cocrystal component ionization and micellar
solubilization. This treatment identified the existence
of a CSC and the factors that determine its value:
(1) cocrystal Ksp and solubility relative to drug, (2)
ionization of cocrystal components, (3) micellar solu-
bilization of cocrystal components, (4) cocrystal stoi-
chiometry, and (5) surfactant CMC. CSC is predicted
to increase with increasing cocrystal solubility, ion-
ization, coformer Ks, and surfactant CMC and with
decreasing drug Ks.
For this series of CBZ cocrystals, the magnitude of
the CSC is mostly influenced by the cocrystal Ksp, sto-
ichiometry, and coformer ionization. Between cocrys-
tals of the same stoichiometry such as CBZ–SLC and
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Figure 11. Influence of SLS on the solubility of CBZ–SLC and CBZD. The lines represent
predictions according to Equations 13 and 14 from two different CMC values: (a) 9 mM and (b)
6 mM. Symbols (circles and triangles) represent the experimental values.
CBZ–SAC, the experiments confirm the prediction
that higher solubility relative to the drug results in a
higher CSC (Table 3). These have similar percentage
ionized (since pH ≈ pKa of the coformer), and KsHA

 KsR. The CSC is mainly determined by the cocrys-
tal solubility relative to the drug. Similar behavior
is observed for 2:1 cocrystals CBZ–4ABA-HYD and
CBZ–SUC. These cocrystals have low levels of ioniza-
tion under the pH conditions studied (10%–20% of the
coformer ionized), and negligible coformer solubiliza-
tion. The experiments also show that the 2:1 cocrystal
CBZ–SUC has a higher CSC than the 1:1 cocrystal
Figure 12. Calculated CSC (mM SLS) and pHmax for CBZ
cocrystals according to Equations 18, 24, and 26 using mea-
sured values presented in Table 2. CSC dependence on pH
may be tailored based on the ionization properties of the
coformer.
CBZ–SAC of equal solubility (in terms of CBZ moles).
The higher CSC of drug rich stoichiometries is a con-
sequence of the higher surfactant concentrations re-
quired to solubilize more drugs to achieve the same
level of coformer enrichment in the aqueous pseudo
phase as a 1:1 cocrystal.
The pH value at the CSC is pHmax, where the
cocrystal and drug, in this case, are in equilibrium
with solution. The predicted CSC and pHmax values
for the CBZ cocrystals studied are plotted in Figure
12. These were calculated from Equations 18, 24, and
26 using values presented in Table 2. CSC is shown
to be strongly dependent on pH and follows the co-
former ionization behavior. It is recognized that these
calculations assume that ionized components do not
interact with the micelles and that Ka, Ks, and CMC
are independent of solution composition.
CONCLUSIONS
A theoretical treatment that considers the contribu-
tions of cocrystal dissociation, component ionization,
and micellar solubilization demonstrates that surfac-
tants can impart thermodynamic stability to cocrys-
tals that otherwise convert to parent drug solid in
aqueous solutions. The CSC and pHmax represent the
surfactant concentration and solution pH where the
cocrystal is in thermodynamic equilibrium with the
solid drug and solution phases. Therefore, both CSC
and pHmax (in the case of ionizable cocrystal compo-
nents) are key indicators of cocrystal stability. This
behavior is confirmed by the stabilization of several
CBZ cocrystals in SLS micellar solutions.
How effective a surfactant is in changing the ther-
modynamic stability of a cocrystal, CSC, and pHmax is
determined mostly by the differential solubilization
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of cocrystal components by micelles. Such differen-
tial solubilization of cocrystal components leads to a
lower rate of solubility increase with surfactant mi-
cellar concentration for the cocrystal, compared with
that of the drug solubility increase (when the drug
has superior micellar solubilization of cocrystal com-
ponents).
For cocrystals of nonionzable, hydrophobic drugs
with ionizable, hydrophilic coformers, the theoretical
treatment predicts that surfactant CSC is decreased
by: (1) preferential drug solubilization (KsR  KsHA),
(2) low ionization of coformer, (3) low cocrystal aque-
ous solubility relative to drug, and (4) cocrystal stoi-
chiometries that are lower in drug than coformer. This
generalization assumes that there is no additional
solution complexation and that ionized coformer is
not solubilized by the micelles. The relationship be-
tween CSC and pHmax is determined by the ionization
behavior of the coformer, with CSC changing orders
of magnitude at pH values where coformer ionizes.
Acidic coformers exhibit an increase in pHmax with
increasing surfactant concentration, whereas ampho-
teric coformers exhibit pHmax decrease and increase.
Critical stabilization concentration and pHmax for
cocrystals in micellar solutions are quantitatively
predicted by mathematical models from solution
phase properties of cocrystal (Ksp), cocrystal compo-
nents (Ks and Ka), and surfactant (CMC). CSC, pHmax,
and cocrystal solubility predicted by the models are
in very good agreement with the experimental mea-
surements. The proposed models provide a rational
basis for selecting additives and solution conditions to
achieve desired cocrystal solubility/stability from pa-
rameter values that are generally available in the lit-
erature or experimentally accessible. Because cocrys-
tals owe their solubility to the ionization and associa-
tion of their components in solution, it is essential to
consider the influence of solution conditions such as
pH and presence of surfactants and other additives
for meaningful cocrystal assessment and selection.
ACKNOWLEDGMENTS
We gratefully acknowledge the financial support from
the Warner-Lambert/Parke Davis Fellowship and the
Upjohn Fellowship from the College of Pharmacy, the
University of Michigan.
REFERENCES
1. Fleischman SG, Kuduva SS, McMahon JA, Moulton B,
Walsh RDB, Rodrı́guez-Hornedo N, Zaworotko MJ. 2003.
Crystal engineering of the composition of pharmaceutical
phases: Multiple-component crystalline solids involving car-
bamazepine. Cryst Growth Des 3(6):909–919.
2. Childs SL, Hardcastle KI. 2007. Cocrystals of piroxicam with
carboxylic acids. Cryst Growth Des 7(7):1291–1304.
3. Nehm SJ, Rodrı́guez-Spong B, Rodrı́guez-Hornedo N. 2006.
Phase solubility diagrams of cocrystals are explained by sol-
ubility product and solution complexation. Cryst Growth Des
6(2):592–600.
4. Bethune SJ, Huang N, Jayasankar A, Rodrı́guez-Hornedo N.
2009. Understanding and predicting the effect of cocrystal
components and pH on cocrystal solubility. Cryst Growth Des
9(9):3976–3988.
5. Jayasankar A, Reddy LS, Bethune SJ, Rodrı́guez-Hornedo N.
2009. Role of cocrystal and solution chemistry on the formation
and stability of cocrystals with different stoichiometry. Cryst
Growth Des 9(2):889–897.
6. Remenar JF, Peterson ML, Stephens PW, Zhang Z, Zimenkov
Y, Hickey MB. 2007. Celecoxib:Nicotinamide dissociation: Us-
ing excipients to capture the cocrystal’s potential. Mol Pharm
4(3):386–400.
7. McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy
J, Shet MS, Mannion R, O’Donnell E, Park A. 2006. Use of a
glutaric acid cocrystal to improve oral bioavailability of a low
solubility API. Pharm Res 23(8):1888–1897.
8. Yadav AV, Dabke AP, Shete AS. Crystal engineering to im-
prove physicochemical properties of mefloquine hydrochloride.
Drug Dev Ind Pharm 36(9):1036–1045.
9. Christian SD, Scamehorn JF. 1995. Solubilization in surfac-
tant aggregates. Marcel Dekker, Inc., New York, New York.
10. Strickley RG. 2004. Solubilizing excipients in oral and in-
jectable formulations. Pharm Res 21(2):201–230.
11. Wiedmann TS, Kamel L. 2002. Examination of the sol-
ubilization of drugs by bile salt micelles. J Pharm Sci
91(8):1743–1764.
12. Wiedmann TS, Bhatia R, Wattenberg LW. 2000. Drug solubi-
lization in lung surfactant. J Control Release 65(1–2):43–47.
13. Serajuddin ATM, Sheen P-C, Mufson D, Bernstein DF, Augus-
tine MA. 1988. Physicochemical basis of increased bioavailabil-
ity of a poorly water-soluble drug following oral administration
as organic solutions. J Pharm Sci 77(4):325–329.
14. Serajuddin ATM. 1999. Solid dispersion of poorly water-
soluble drugs: Early promises, subsequent problems, and re-
cent breakthroughs. J Pharm Sci 88(10):1058–1066.
15. Rodrı́guez-Hornedo N, Nehm SJ, Jayasankar A. 2006. Cocrys-
tals: Design, properties and formation mechanisms. In Ency-
clopedia of Pharmaceutical Technology, Eds. Swarbrick and
Boylan, Informa Health Care, London; 3rd ed. pp 615–635.
16. Rodrı́guez-Hornedo N, Nehm SJ, Seefeldt KF, Pagan-Torres Y,
Falkiewicz CJ. 2006. Reaction crystallization of pharmaceuti-
cal molecular complexes. Mol Pharm 3:362–367.
17. Bak A, Gore A, Yanez E, Stanton M, Tufekcic S, Syed R,
Akrami A, Rose M, Surapaneni S, Bostick T, King A, Neervan-
nan S, Ostovic D, Koparkar A. 2008. The co-crystal approach
to improve the exposure of a water-insoluble compound: AMG
517 sorbic acid co-crystal characterization and pharmacoki-
netics. J Pharm Sci 97(9):3942–3956.
18. Schultheiss N, Newman A. 2009. Pharmaceutical cocrys-
tals and their physicochemical properties. Cryst Growth Des
9(6):2950–2967.
19. Huang N, Rodrı́guez-Hornedo N. 2010. Effect of micellar sol-
ubilization on cocrystal solubility and stability. Cryst Growth
Des 10(5):2050–2053.
20. Huang N, Rodrı́guez-Hornedo N. 2011. Engineering cocrys-
tal thermodynamic stability and eutectic points by micel-
lar solubilization and ionization. CrystEngComm 13(17):409–
5422.
21. Nordström FL, Rasmuson ÅC. 2006. Solubility and melting
properties of salicylic acid. J Chem Eng Data 51(5):1668–1671.
22. Williamson DS, Nagel DL, Markin RS, Cohen SM. 1987. Effect
of pH and ions on the electronic structure of saccharin. Food
Chem Toxicol 25(3):211–218.
23. Kojima S, Ichigabase H, Iguchi S. 1966. Studies on sweetening
agents. VII. Absorption and excretion of sodium cyclamate (2).
Chem Pharm Bull 14(9):965–971.
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 100, NO. 12, DECEMBER 2011
5234 HUANG AND RODRÍGUEZ-HORNEDO
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